Please check your internet connection and try again.
# Tabuphos
## Overview
Tabuphos is a phosphate supplement used to treat or prevent hypophosphatemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypophosphatemia.
## Adult Dosing
* **Oral:** Dosing is highly individualized based on serum phosphate levels and clinical status. Common oral doses range from 1,000 to 3,000 mg of elemental phosphorus per day, divided into multiple doses.
* **Intravenous:** Dosing is based on the severity of hypophosphatemia and patient weight. Typically, doses range from 0.08 to 0.16 mmol/kg (2.5 to 5 mg/kg) of elemental phosphorus per dose, administered intravenously over 3 to 6 hours. The maximum daily dose should not exceed 12 mmol/kg (372 mg/kg) of elemental phosphorus. Local protocols often dictate specific IV dosing regimens.
## Pediatric Dosing
* Dosing in pediatric patients is less established and should be determined by a specialist. Oral doses are typically based on elemental phosphorus requirements, while IV doses are often calculated per kg of body weight, similar to adults but with careful titration and monitoring.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Reduced doses may be necessary. Monitor serum phosphate and calcium levels closely.
* **Hepatic Impairment:** No specific dose adjustments are typically required, but monitor electrolytes.
## Contraindications
* Hyperphosphatemia
* Hypersensitivity to the drug or its components
* Conditions where phosphate administration is contraindicated (e.g., hypercalcemia, severe renal insufficiency).
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain (oral).
* **Serious:** Hyperphosphatemia, hypocalcemia, hyperkalemia, hypotension, cardiac arrhythmias (especially with rapid IV infusion).
## Key Drug Interactions
* **Antacids containing aluminum or magnesium:** May decrease absorption of phosphate. Administer at least 2 hours apart.
* **Iron supplements:** May decrease absorption of both.
* **Tetracyclines:** May decrease absorption of both.
* **Vitamin D analogues:** May increase the risk of hypercalcemia and hyperphosphatemia.
## Monitoring
* Serum phosphate levels
* Serum calcium levels
* Serum potassium levels
* Renal function (BUN, creatinine)
* Urine output
## Clinical Pearls
* Oral formulations can cause significant gastrointestinal upset; consider dividing doses or using stool softeners.
* Rapid intravenous infusion of phosphate can lead to severe hypotension and cardiac complications. Always administer slowly and monitor the patient closely.
* Correcting severe hypophosphatemia can be complex and requires careful electrolyte management.
***
*This information is intended for clinical professionals. Always consult the most current prescribing information and local protocols before making any therapeutic decisions.*
